RxDoctor Payments Data

Arthur Mandelin, MD

Rheumatology · Chicago, ILNPI 1669655569

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $217,389 of the $269,664 with a category attached, or 80.6%. 19 manufacturers reported payments, led by Pfizer at 52.0% of the total. Reporting peaked in 2019 at $129,630 and has fallen 89.0% since, to $14,273 in 2025. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$269,664in general payments, 2019–2025

Across 397 payments — averaging $679.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$140K
  • AbbVie$53K
  • Lilly USA, LLC$35K
  • Sanofi$15K
  • Amgen$12K
  • E.r. Squibb & Sons, L.L.C.$5K
  • plus $10K from 13 others

What the payments were for

  • Consulting fees$9,2733%
  • Speaking & faculty fees$217,38981%
  • Travel & lodging$33,51612%
  • Food & beverage$8,6423%
  • Education$8450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$269,664 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,639,758
Medicare patients
556
Services billed
98,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib69$501,283
Humira(Cf) PenAdalimumab47$467,993
Enbrel SureclickEtanercept65$452,875
Xeljanz XrTofacitinib Citrate58$339,922
XeljanzTofacitinib Citrate31$190,464
Actemra ActpenTocilizumab34$127,611
Orencia ClickjectAbatacept23$122,283
Humira PenAdalimumab13$89,415
Cosentyx Unoready PenSecukinumab11$76,549
KevzaraSarilumab16$68,373
OlumiantBaricitinib11$30,092
LyricaPregabalin13$10,668
Leflunomide80$6,677
MethotrexateMethotrexate Sodium219$6,574
Hydroxychloroquine Sulfate165$6,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$53,089$501,28369 claims
PfizerXeljanz, Lyrica$140,342$201,13144 claims
SanofiKevzara$15,293$68,37316 claims
Lilly USA, LLCOlumiant$34,585$30,09211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →